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S95.e2 Lai et alBackground: Staging schemas have changed multiple times over the past 10 years.Objective: We sought to examine the impact of staging schemas on the distribution of stages at diagnosis
over time.Methods: We examined the stage at diagnosis for melanoma cancer cases diagnosed between 1999 and
2006 using data provided by the Surveillance, Epidemiology, and End Results (SEER) and National Program
of Cancer Registries (NPCR) programs. The staging schemas were summary staging 1977 (SS1977),
summary staging 2000 (SS2000), derived SS2000, and SEER historic staging systems.Results: Melanoma was predominantly staged as a localized disease in all schemas. Using SEER data, the
proportion of localized melanomas diagnosed in 2001 to 2003 using SS2000 was about 2.5% lower than the
proportion diagnosed in 1999 to 2000 using SS1977, whereas the proportion of cases staged as regional was
2.7% higher using the SS2000 than SS1977. The distribution of stages for cases diagnosed in 2001 to 2003
using SS2000 was similar to that for cases diagnosed in 2004 to 2006 using a derived SS2000. Shift in stage
distribution among SS1977, SS2000, and SEER historic staging was found to be about 6% (localized to
regional) and about 17.5% (unknown to regional stage). The distribution of changes in stage observed for
the SEER cases was not evident for cases from NPCR.Limitations: SEER historic staging was not available for NPCR cases.Conclusion: Changes in staging rules resulted in cases being moved from the localized to the regional
stage and from unknown to the regional stage. Without staging rules that have been consistently applied to
melanomas over many years, surveillance of prevention, treatment, and control of this condition is difficult.
( J Am Acad Dermatol 2011;65:S95.e1-10.)
Key words: derived summary staging 2000; malignant melanoma; stages at diagnosis; summary staging
1977; summary staging 2000; Surveillance, Epidemiology, and End Results historic staging.Cancer staging describes the extent to which a
cancer has spread from its point of origin. Cancer
staging classification schemas are valuable in that
they assist clinicians to understand the extent of the
disease, recommend the best therapy, and provide
prognostic information to patients and their fami-
lies.1-3 From the public health perspective, knowing
the stage of cancer aids public health practitioners
and researchers in assessing the burden of cancer on
society, characterizing prognosis including survivor-
ship, and identifying necessary strategies and poli-
cies to reduce the cancer burden. State registries
report stage distribution of various cancer sites for
routine cancer surveillance. In addition, data on
staging have been used to target subpopulationsthe Kansas Cancer Registry, University of Kansas Medical
entera; and Division of Cancer Prevention and Control,
ational Center for Chronic Disease Prevention and Health
omotion, Centers for Disease Control and Prevention,
tlanta.b
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Several staging classification systems are used in
clinical practice, such as the TNM (tumor-nodes-
metastasis) staging system of the American Joint
Committee on Cancer.2,3 The National Cancer
Institute Surveillance, Epidemiology, and End
Results (SEER) summary staging was intended as a
measure for cancer surveillance with longitudinal
stability for population-based cancer registries.7
Three staging schemas have been used in the last 2
decades: (1) summary staging 1977 (SS1977) for
cases diagnosed in 1995 to 2000, (2) summary
staging 2000 (SS2000) for cases diagnosed in 2001The opinions or views expressed in this supplement are those of
the authors and do not necessarily reflect the opinions,
recommendations, or official position of the journal editors or
the Centers for Disease Control and Prevention.
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System (also called derived summary staging/de-
rived SS2000) for cases diagnosed in 2004 to the
present.4,8,9 The most recent change from SS2000 to
derived SS2000 suggests that staging systems will
continue to change as oncologists and researchers
learn more about cancer.CAPSULE SUMMARY
d Knowledge of melanoma cancer stage
aids public health practitioners and
researchers in assessing the burden on
society.
d Staging facilitates the identification of
necessary strategies and/or policies to
reduce the burden on society.
d Staging rules have changed.
Understanding the impact of staging
rule changes and the associated
limitations of staging data would help
with interpretation of the data and
related implications for cancer control.Although cancer staging
remains a critical tool in mea-
suring the success of cancer
control efforts, there is a need
to study and evaluate the im-
pact of changes in staging
schemas on cancer reporting.
In fact, two studies found
inconsistencies in changes
from SS1977 to SS2000 across
cancer sites.10,11 For mela-
noma, the major shift oc-
curred when cases classified
as localized stage using
SS1977 changed to regional
stage using SS2000.11
To reduce longitudinal in-
consistencies by producing
uniform staging information
for all registered cases over time, the SEER program
constructed a variable known as the SEER historic
summary stage (SHSS).12 However, collection of the
SHSS was not implemented in the National Program
of Cancer Registries (NPCR). Therefore, this article
addresses the following: first, using SEER data, we
show the differences in the distribution of stages of
melanoma by the 3 staging schemas and the SHSS.
Second, using NPCR data, we show the distribution
of stages of melanoma by the 3 staging schemas and
then estimate the stage of NPCR-reported cases using
the results observed in stage shift among the 3
schemas and the SHSS. This projection attempts to
determine whether the projected SHSS can assist
NPCR in monitoring and evaluating public health
efforts designed to increase screening, early detec-
tion, and control of melanoma cancer over time.
METHODS
We used data submitted to the NPCR program as
of November 30, 2008, for registries that met the US
Cancer Statistics publication standards for data qual-
ity for all sites combined.13 We also used data from
the November 2008 submission to the SEER pro-
gram. To address stage changes in melanoma
reporting affected by the 3 staging schemas, we
used microscopically confirmed invasive melanoma
cases diagnosed between 1999 and 2006 using
the International Classification of Diseases forOncology, Third Edition codes 8720 to 8790.13 The
33 NPCR that met the US Cancer Statistics publication
standards for the entire time period 1999 to 2006 are
shown in Fig 1. The coverage from these NPCR
accounted for 63.1% of the US population for those
years. The SEER-11 registries, which covered 13.7%
of the US population, are also included in this articleto address the effects of
changes in staging schema
on melanoma cancers (Fig
1). Therefore, the total US
population coverage in this
study is 67.2% after removing
population served by the
SEER metropolitan cancer
registries and was also in-
cluded in the corresponding
NPCR state cancer registries.
However, we could not as-
sess the extent of duplicate
case counting because of the
nature of deidentified data.
We categorized the stage
at diagnosis reported in the
NPCR using SS1977 for cases
diagnosed in 1999 to 2000,SS2000 for cases diagnosed in 2001 to 2003, and
derived SS2000 for cases diagnosed in 2004 to 2006.
All cancer staging systems have an underlying sim-
ilarity. Each system is based on documentation of the
‘‘extent of disease,’’ a detailed description of the
spread of the disease from the site of origin. In
general, summary staging is a single-digit system and
has 8 categories: in situ, localized only, regional by
direct extension only, regional lymph node(s) in-
volved only, both regional lymph node(s) and
regional extension, regional not otherwise specified,
distant site(s) and/or distant lymph node(s) in-
volved, and unknown. Details of these staging sys-
tems can be found elsewhere.13,14 The derived
SS2000 system uses a modified extent of disease
format (more detailed than the summary staging
system) to collect information about each case.
Briefly, the data items specific to melanoma are
extracted from the medical record and coded using
the derived SS2000 system fields. When data collec-
tion is complete, the data collector activates the
computer algorithms to derive the values for SS2000,
and the computer algorithms determine the classifi-
cation stages in a consistent manner.
The SHSS was available for all cases reported to
the SEER registries, although it was not calculated or
collected by NPCR. The SHSS was never directly
coded by SEER registries; instead, it was derived
from the extent of disease, which captured
Abbreviations used:
derived SS2000: Collaborative Stage Data Collec-
tion System/derived summary
staging 2000
NPCR: National Program of Cancer
Registries
SEER: Surveillance, Epidemiology, and
End Results
SHSS: Surveillance, Epidemiology, and
End Results historic summary
staging
SS1977: summary staging 1977
SS2000: summary staging 2000
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node involvement, and metastases to other tis-
sues.9,15,16 However, the concepts of this schema
were used consistently over time so that SEER long-
term trends could be assessed.4 Although staging in
SHSS is based on the same concepts as SS1977,
SS2000, and derived SS2000, the specific definitions
of various stages within each differ. All versions of
extent-of-disease characterization allow derivation
of historic stage categories. In spite of the differ-
ences, all schemas categorize cases as in situ,
localized, regional (regional by direct extension
only, regional lymph node(s) involved only, re-
gional by both direct extension and lymph node
involvement, regional not otherwise specified),
distant, and unknown. But there are differences
among the 3 schemas (Table I). For example, Clark
level V (ie, depth of lesion[4.0 mmwith or without
ulceration), which was considered a localized stage
in the SS1977 schema, was categorized as a regional
stage in both SS2000 and SHSS.
Simple descriptive statistics were used to sum-
marize the distribution of stage at diagnosis by year
and staging schema. We used the kappa statistic to
derive the level of agreement among the SHSS, the
SS1977, the SS2000, and the derived SS2000. We
considered a kappa statistic greater than 0.75 to be
excellent agreement, a kappa statistic between
0.40 and 0.75 to be fair to good agreement, and a
kappa statistic below 0.40 to be very low or no
agreement.
NPCR used the SS1977, the SS2000, and the
derived SS2000 to classify stage of cancers diag-
nosed in 1999 to 2006. Because NPCR did not stage
these cases using the SHSS, the distribution of
stages according to SHSS had to be estimated. We
used an equation that captures the stage shift of
cases to obtain the projected stages for NPCR cases
according to the SHSS rules (Table I). The equations
shown are for cases diagnosed in 1999 and 2000
using SS1977.NSHSS; localized ¼ NSS1977; localized NSS1977; localized
 plocalized to regional ð1Þ
NSHSS; regional ¼ NSS1977; regional1NSS1977; localized
 plocalized to regional1NSS1977; unk
 punk to regional ð2Þ
NSHSS; distant ¼ NSS1977; distant ð3Þ
NSHSS; unk ¼ NSS1977; unk NSS1977; unk
 punk to regional ð4Þ
Where,
NSHSS,i = estimated number of NPCR cases in stage
i when SHSS is used, where i = localized, regional,
distant, and unknown (unk)
NSS1977,i = the number of NPCR cases in stage i
when SS1977 is used, where i = localized, regional,
distant, and unknown (unk)
pij = the proportion of SEER cases that showed a
shift from stage i (using SS1977) to stage j (using
SHSS).
The same formulas can be applied to cases diag-
nosed from 2001 to 2003 using SS2000.RESULTS
We included 55,665 cases of invasive melanoma
cancer of the skin from the SEER registries in the
analysis. The proportions of cases categorized as
localized, regional, distant, and unknown by diag-
nosis years are shown in Table II. Cases over the
years of diagnosis were collapsed within each stag-
ing system because their distribution by year ap-
peared similar. The proportions of cases diagnosed
in 1999 to 2000 categorized to each corresponding
stage according to SS1977 schema were 87.8% ([5442
1 5652]/[6221 1 6413]), 5.3%, 3.2%, and 3.7%,
whereas the proportions of cases diagnosed in
2001 to 2003 categorized to each corresponding
stage using SS2000 were 85.3%, 8.0%, 3.4%, and
3.3%. The distribution of stages at diagnosis for cases
categorized in 2001 to 2003 using SS2000 was similar
to that for cases diagnosed in 2004 to 2006 using
derived SS2000.
As we looked at the shift in stages among the 3
systems (SS1977, SS2000, and derived SS2000) and
the SHSS, we noted that about 6% of localized
melanomas using the SS1977 and SS2000 moved to
the regional stage using the SHSS. About 17.5% of
the unknown cases using the SS1977 and SS2000
Fig 1. Thirty-three NPCR and 11 SEER cancer registries that were included in the analysis.
NPCR, National Program of Cancer Registries; SEER, Surveillance, Epidemiology, and End
Results.
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changes resulted in an increase in regional stage
cases. Finally, the distribution of stages for cases
diagnosed in 2004 to 2006 was identical in the SHSS
and the derived SS2000. The level of agreement
characterized by the kappa statistic was 0.77 be-
tween the SS1977 and SHSS, 0.82 between the
SS2000 and SHSS, and 1.0 between the derived
SS2000 and SHSS.
NPCR reported a total of 272,074 melanoma
cancers in 1999 to 2006, with the number of
reported cases increasing each year (Table III).
Despite the increasing number of cases reported,
the distribution of stages at diagnosis remained
quite stable. The distribution of localized, regional,
distant, and unknown stages at diagnosis within
each staging system showed 78.3%, 7.0%, 3.8%, and
10.9% for 1999 to 2000 diagnosed cases and 78.6%,
8.1%, 3.7%, and 9.6% for 2001 to 2003 diagnosed
cases. The proportions of localized and distant
stages were almost identical in the two time periods
using the SS1977 and the SS2000. The proportion of
regional stage cases went up from 7.0% to 8.1%
whereas those in the unknown stage went down
from 10.9% to 9.6% between 1999 to 2000 and 2001
to 2003 (or SS1977 to SS2000). The proportion of
regional staged cancer cases diagnosed in 2004 to2006 was 9% and the proportion of unknown cases
was 8.4%.
The projected SHSS stage at diagnosis, based on
shifting the stages of cases reported to NPCR, is
shown in Table III. For example, there were 22,380
localized melanomas diagnosed in 1999 in the com-
bined NPCR. For 1999 SEER diagnoses, a proportion
of 0.064 of localized stage cases (348/5442) (Table II)
was shifted from being localized using the SS1977
system to regional using the SHSS system. Using the
SHSS proportion as the standard, the projected
number of localized cases for NPCR was 20,949
(ie, 22,380e [22,380 * 0.064]). Similarly, the projected
number of regional cases became 3956 (19641 1432
[22,380 * 0.064; moved from localized to regional] 1
560 [3126 * 0.179; moved from unknown to re-
gional]). Overall, the projected proportion of local-
ized stage melanomas ranged from 73.3% in 1999 to
78.8% in 2006 whereas the proportion of regional
stage melanomas ranged from 13.8% in 1999 to 9.2%
in 2006.
DISCUSSION
We observed an increase of 2.7% (from 5.3%-
8.0%) in regional stage cases from 1999 through
2000 (SS1977) to 2001 through 2003 (SS2000) for
the SEER registries, and an increase of only 1.1%
Table I. Known staging criteria differences among summary staging 1977, summary staging 2000, and
Surveillance, Epidemiology, and End Results historic summary stage schemas
Stage SS1977 SS2000 SHSS
1 - Localized only Subcutaneous tissue invaded
(through entire dermis)
Clark level* II-V including
NOS with or without
ulcerationy
Clark level II-IV including
NOS with or without
ulceration
Clark level II-IV including
NOS without ulceration
Regional, including
d Regional by direct
extension only
d Regional lymph
node(s) involved only
d Regional by BOTH
direct extension and
regional lymph node(s)
involved
d Regional, NOS
Subcutaneous tissue invaded
(through entire dermis)
Clark level V with or
without ulceration
Lip: Facial, NOS
Lip: Facial, NOS: Buccinator
(buccal)
Lip: Facial, NOS: Nasolabial
Lip: Mandibular, NOS:
Submental
Lip: Parotid, NOS
Lip: Parotid, NOS: Infra-
auricular
Lip: Parotid, NOS: Preauricular
Eyelid/canthus: Mandibular,
NOS: Submental
Face, Other (cheek, chin,
forehead, jaw, nose, and
temple): Mandibular, NOS:
Submental
Neck: Mandibular, NOS:
Submental
Subcutaneous tissue invaded
(through entire dermis)
Clark level V with or without
ulceration
Clark level II-IV including
NOS with ulceration
Extension unknown and
known lymph node
involvement
7 - Distant site(s)/lymph
node(s) involved
Lip: Facial, NOS
Lip: Facial, NOS: Buccinator
(buccal)
Lip: Facial, NOS: Nasolabial
Lip: Mandibular, NOS:
Submental
Lip: Parotid, NOS
Lip: Parotid, NOS:
Infra-auricular
Lip: Parotid, NOS: Preauricular
Eyelid/canthus: Mandibular,
NOS: Submental
Face, Other (cheek, chin,
forehead, jaw, nose, and
temple): Mandibular, NOS:
Submental
Neck: Mandibular, NOS:
Submental
Lip: Facial, NOS
Lip: Facial, NOS: Buccinator
(buccal)
Lip: Facial, NOS: Nasolabial
Lip: Mandibular, NOS:
Submental
Lip: Parotid, NOS
Lip: Parotid, NOS:
Infra-auricular
Lip: Parotid, NOS: Preauricular
Eyelid/canthus: Mandibular,
NOS: Submental
Face, Other (cheek, chin,
forehead, jaw, nose, and
temple): Mandibular, NOS:
Submental
Neck: Mandibular, NOS:
Submental
9 - Unknown if extension
or metastasis
Extension unknown Extension unknown Extension unknown and
unknown lymph node
involvement
Boldface and italics are used to demonstrate the shifting between the staging schemas.
NOS, Not otherwise specified; SS1977, summary stage 1977; SS2000, summary stage 2000; SHSS, Surveillance, Epidemiology, and End Results
historic summary stage.
*Clark level: measure of thickness of melanoma in subcutaneous skin layers.
ySkin ulceration does not alter classification in SS1977 and SS2000.
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Table II. Stages of melanoma cancer cases: Surveillance, Epidemiology, and End Results registries, 1999 to 2006
Diagnosis year/staging schema n % Yearly
SHSS
Localized Regional Distant Unknown
1999/SS1977 (N = 6221) 5094 711 210 206
Localized 5442 87.5 5094 348 0 0
Regional 318 5.1 0 318 0 0
Distant 210 3.4 0 0 210 0
Unknown 251 4.0 0 45 0 206
2000/SS1977 (N = 6413) 5294 747 194 178
Localized 5652 88.1 5294 358 0 0
Regional 353 5.5 0 353 0 0
Distant 194 3.0 0 0 194 0
Unknown 214 3.4 0 36 0 178
2001/SS2000 (N = 6800) 5525 876 236 163
Localized 5838 85.8 5525 313 0 0
Regional 523 7.7 0 523 0 0
Distant 236 3.5 0 0 236 0
Unknown 203 3.0 0 40 0 163
2002/SS2000 (N = 6692) 5381 900 239 172
Localized 5700 85.2 5381 319 0 0
Regional 544 8.1 0 544 0 0
Distant 239 3.6 0 0 239 0
Unknown 209 3.1 0 37 0 172
2003/SS2000 (N = 6807) 5400 962 226 219
Localized 5770 84.8 5400 370 0 0
Regional 551 8.1 0 551 0 0
Distant 226 3.3 0 0 226 0
Unknown 260 3.8 0 41 0 219
2004/Derived SS2000 (N = 7209) 6152 621 260 176
Localized 6152 85.3 6152 0 0 0
Regional 621 8.6 0 621 0 0
Distant 260 3.6 0 0 260 0
Unknown 176 2.5 0 0 0 176
2005/Derived SS2000 (N = 7810) 6716 669 289 136
Localized 6716 86.0 6716 0 0 0
Regional 669 8.6 0 669 0 0
Distant 289 3.7 0 0 289 0
Unknown 136 1.7 0 0 0 136
2006/Derived SS2000 (N = 7713) 6580 681 286 166
Localized 6580 85.3 6580 0 0 0
Regional 681 8.8 0 681 0 0
Distant 286 3.7 0 0 286 0
Unknown 166 2.2 0 0 0 166
Data are from population-based cancer registries that participate in SEER program that meet high-quality data criteria. These registries cover
13.7% of US population for 1999-2006.
SS1977, Summary stage 1977; SS2000, Summary stage 2000; SHSS, Surveillance, Epidemiology, and End Results (SEER) historic summary
stage.
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period for the NPCR. This observed pattern of
melanoma cases in SEER registries that were found
shifting from one stage to another were mostly a
result of changes in staging rules. Clark level V with
or without ulceration that was considered a local-
ized stage in SS1977 has been moved to a regional
stage in both SS2000 and SHSS. On the other hand,
for sites lips, neck, face, and eyelids with certainhistologies the stage moved from distant to regional
(Table I). For the NPCR cases, we have seen an
increase in counts of localized cases, but we did not
observe the expected decrease of about 2.5% in
localized cases as was seen for the SEER registries.
In fact, there was practically no change in propor-
tion of localized stage for the NPCR from the period
1999 through 2000 to the period 2001 through
2003 (78.3% vs 78.6%). This inconsistency in stage
Table III. Reported and projected stages of
melanoma cancer cases: National Program of
Cancer Registries, 1999 to 2006
Year of diagnosis
NPCR-reported
stage
Projected
SHSS staging*
n % Count %
1999/SS1977 (N = 28,575)
Localized 22,380 78.3 20,949 73.3
Regional 1964 6.9 3956 13.8
Distant 1105 3.9 1105 3.9
Unknown 3126 10.9 2566 9.0
2000/SS1977 (N = 30,466)
Localized 23,879 78.4 22,366 73.4
Regional 2155 7.1 4226 13.9
Distant 1114 3.6 1114 3.7
Unknown 3318 10.9 2760 9.0
2001/SS2000 (N = 32,718)
Localized 25,701 78.5 24,323 74.3
Regional 2570 7.9 4597 14.1
Distant 1151 3.5 1151 3.5
Unknown 3296 10.1 2647 8.1
2002/SS2000 (N = 34,149)
Localized 26,855 78.6 25,352 74.2
Regional 2783 8.2 4871 14.3
Distant 1208 3.5 1208 3.5
Unknown 3303 9.7 2718 8.0
2003/SS2000 (N = 34,255)
Localized 26,904 78.6 25,179 73.6
Regional 2855 8.3 5073 14.8
Distant 1338 3.9 1338 3.9
Unknown 3128 9.2 2635 7.7
2004/Derived SS2000
(N = 36,093)
Localized 28,118 77.9 28,118 77.9
Regional 3212 8.9 3212 8.9
Distant 1457 4.0 1457 4.0
Unknown 3306 9.2 3306 9.2
2005/Derived SS2000
(N = 38,758)
Localized 30,779 79.4 30,779 79.4
Regional 3461 8.9 3461 9.0
Distant 1405 3.6 1405 3.6
Unknown 3113 8.1 3113 8.0
2006/Derived SS2000
(N = 37,090)
Localized 29,234 78.8 29,234 78.8
Regional 3413 9.2 3413 9.2
Distant 1423 3.8 1423 3.8
Unknown 3020 8.2 3020 8.2
Data are from population-based cancer registries that participate
in NPCR that meet high-quality data criteria. These registries cover
63.1% of population for 1999 to 2006.
NPCR, National Program of Cancer Registries; SHSS, Surveillance,
Epidemiology, and End Results historic summary stage; SS1977,
summary stage 1977; SS2000, summary stage 2000.
*Calculation of projected SHSS stage can be referred to equations
1 to 4 in ‘‘Methods’’ section.
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discussed below.
The steadily increasing case counts since 1999
give evidence of incomplete reporting of melanoma
cancers by some NPCR in the early years of the
registries. In fact, underreporting has long been
suspected for melanomas.17-20 If underreporting
from physicians’ offices is believed to have occurred,
particularly in the early years of the registries, we
would expect to see a higher proportion of localized
disease within each staging schema than is currently
shown in Table III. One possible reason for not
seeing an increase in the proportion of localized
stage could be misclassification because of lack of
some staging elements. For example, some of the
high percentage of NPCR cases currently classified as
unknown stage (;10%) could be a result of incom-
plete information obtained solely from pathology
reports. These pathology-report-only cases have not
yet been followed up with physicians’ offices for
definitive determination of stages.18,21 This could
explain why we did not see a decrease in the
proportion of localized NPCR cases between 1999
to 2000 and 2001 to 2003. Because underreporting
may havemasked the changes in staging distribution,
the projected SHSS staging distribution changes,
particularly before 2004, may not be as meaningful
for the NPCR as they were for the SEER registries.
Approximately 10% currently staged as unknown
reported to NPCR between 1999 to 2000 and 2001 to
2003 could potentially be reclassified when addi-
tional sources of information are obtained. This
occurred for the SEER registries when a number of
unknown cases were moved from SS1977 and
SS2000 into the regional category under the SHSS
system. We examined the distribution of stages at
diagnosis for cases diagnosed in 2004 to 2006 when
most NPCR had better case ascertainment of mela-
noma cancers. For those cases, the distribution of
localized, regional, distant, and unknown stages
at diagnosis was 78.8%, 9.0%, 3.8%, and 8.4% for
NPCR-reported cases whereas the distribution for
the SEER registries was 85.5%, 8.7%, 3.7%, and 2.1%.
If about 6% of NPCR unknown cases for 2004 to
2006 were recategorized as localized stage after
additional information was obtained, then the distri-
bution of stages at diagnosis would be about the
same for cases diagnosed in 2004 to 2006 in both
surveillance programs. This would allow the stages
projected at diagnosis to be useful for NPCR cases in
guiding public health practitioners as they monitor
melanoma prevention, screening, and control efforts
over time (Table III).
On the other hand, if the approximately 10%
unknown stage cases that were reported to NPCR
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recategorized as localized after follow-up with
health care providers, then the projected stages for
NPCR-reported cases, even for those diagnosed in
2004 to 2006, may not be as useful for the purpose of
trend analysis over time. In that case, further evalu-
ation would be needed to determine why there are
differences in stage at diagnosis between the two
programs.
Limitations
This article has some limitations. First, the SEER
historic stage was not available for the NPCR cases,
making it impossible to examine differences in the
distribution of stages of melanoma in the popula-
tions served by the two programs. Second, restaging
NPCR cases using the SEER historic schema is not
readily feasible because the staging elements were
not collected previously. Third, our study showed
that SEER cases diagnosed from 2004 to 2006 have
the same staging distribution when using both the
derived SS2000 and the SEER historic staging sys-
tems. Unfortunately, we were not able to identify a
source of documentation that could potentially ex-
plain such a perfect agreement in stages between the
two schemas.
CONCLUSION
Melanoma is a potentially preventable cancer that
has been shown to benefit from screening and early
detection.22,23 Public health efforts rely heavily on
surveillance data to monitor the burden of cancer
across subpopulations and to observe trends over
time. These data have also been used to evaluate the
effectiveness of various programs that were imple-
mented to reduce this burden. It is important that
public health practitioners and other users of these
data understand the impact of staging rule changes
and the associated limitations of staging data so that
inaccurate interpretation will not misinform mela-
noma control efforts and affect our ability to respond
appropriately. It is recommended that public health
practitioners and researchers follow up with individ-
ual state registries to understand their level of com-
pleteness in ascertaining melanoma cases. If
individual registries consider their level of ascertain-
ment to be complete even in the years from 1999
to 2004, then the proposed formula for stage con-
version from SS1977 and SS2000 to SHSS schema will
be meaningful for planning and evaluation of mela-
noma cancer prevention and control efforts.
Otherwise monitoring stages of melanoma cancer
over time is not likely feasible and would not be
recommended.REFERENCES
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